Molecular diagnostics of brain tumors using third-generation sequencing

Molecular diagnostics of brain tumors using third-generation sequencing - nanoDx

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00018102

Enrollment

211

Registered

2021-05-21

Start date

2021-10-29

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

brain tumor C70 C71 C72

Interventions

Group 1: Tumor tissue will be subjected to methylation-based classification by nanopore sequencing.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Female or male individuals with planned biopsy or resection of a suspected brain tumor as part of routine clinical procedures, who have given written informed consent.

Exclusion criteria

Exclusion criteria: None.

Design outcomes

Primary

Measure	Time frame
As primary endpoint, we will compare the result of DNA methylation-based classification by nanopore sequencing to match WHO integrated diagnosis as established by routine neuropathological workup.	—

Secondary

Measure	Time frame
Additionally, the time interval from receipt of surgical specimens to complete sequencing report ("time to diagnosis") will be recorded.	—

Countries

Austria, France, Germany, Israel, Norway

Contacts

Public ContactPhilipp Euskirchen

Charité - Universitätsmedizin BerlinKlinik für NeurologieAbteilung für experimentelle Neurologie

philipp.euskirchen@charite.de(030) 450-660535

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026